C-Met modulator pharmaceutical compositions
Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
1. A method of treating kidney cancer, comprising administering to a patient in need of such treatment a tablet pharmaceutical composition comprising:
30-32 percent by weight of Compound I, L-malate salt wherein Compound I is:
38-40 percent by weight of microcrystalline cellulose;
18-22 percent by weight of lactose;
2-4 percent by weight of hydroxypropyl cellulose;
4-8 percent by weight of croscarmellose sodium;
0.2-0.6 percent by weight of colloidal silicon dioxide; and
0.5-1 percent by weight of magnesium stearate;
alone or in combination with another therapeutic agent.
2. The method of claim 1 , wherein the lactose in the tablet pharmaceutical composition is lactose anhydrous.
3. The method of claim 1 , wherein the tablet pharmaceutical composition further comprises a film coating containing hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
4. The method of claim 1 , wherein the tablet pharmaceutical composition contains 20 to 100 mg of Compound I.
5. The method of claim 1 , wherein the tablet pharmaceutical composition contains 20, 25, 50, 60, 75, 80, or 100 mg of Compound I.
6. The method of claim 1 , wherein the kidney cancer is renal cell carcinoma.
7. A method of treating kidney cancer, comprising administering to a patient in need of such treatment a tablet pharmaceutical composition comprising, based on 100 weight/weight percent:
30-32 percent by weight of Compound I, L-malate salt wherein Compound I is:
38-40 percent by weight of microcrystalline cellulose;
18-22 percent by weight of lactose;
2-4 percent by weight of hydroxypropyl cellulose;
4-8 percent by weight of croscarmellose sodium;
0.2-0.6 percent by weight of colloidal silicon dioxide; and
0.5-1 percent by weight of magnesium stearate;
and further comprising a film coating containing hypromellose, titanium dioxide, triacetin, and iron oxide yellow.
8. The method of claim 7 , wherein the lactose in the tablet pharmaceutical composition is lactose anhydrous.
9. The method of claim 7 , wherein the tablet pharmaceutical composition contains 20 to 100 mg of Compound I.
10. The method of claim 7 , wherein the tablet pharmaceutical composition contains 20, 25, 50, 60, 75, 80, or 100 mg of Compound I.
11. The method of claim 7 , wherein the kidney cancer is renal cell carcinoma.
12. A method of treating kidney cancer, comprising administering to a patient in need of such treatment a tablet pharmaceutical composition comprising about:
Ingredient
(% w/w)
Compound I, L-malate salt
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
6.00
Silicon dioxide, Colloidal
0.30
Magnesium Stearate
0.75
Total
100.00
wherein Compound I is:
13. The method of claim 12 , wherein the tablet pharmaceutical composition contains 20 to 100 mg of Compound I.
14. The method of claim 12 , wherein the tablet pharmaceutical composition contains 20, 25, 50, 60, 75, 80, or 100 mg of Compound I.
15. The method of claim 12 , wherein the kidney cancer is renal cell carcinoma.
16. A method of treating kidney cancer, comprising administering to a patient in need of such treatment a tablet pharmaceutical composition comprising about:
Ingredient
(% w/w)
Compound I, L-malate salt
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
3.00
Total Intra-granular
95.95
Silicon dioxide, Colloidal
0.30
Croscarmellose Sodium
3.00
Magnesium Stearate
0.75
Total
100.00
wherein Compound I is:
17. The method of claim 16 , wherein the tablet pharmaceutical composition contains 20 to 100 mg of Compound I.
18. The method of claim 16 , wherein the tablet pharmaceutical composition contains 20, 25, 50, 60, 75, 80, or 100 mg of Compound I.
19. The method of claim 16 , wherein the kidney cancer is renal cell carcinoma.